Original paper

Folia Neuropathologica

Inhibitor of bromodomain and extraterminal domain proteins decreases transcription of Cd33 in the brain of mice subjected to systemic inflammation; a promising strategy for neuroprotection

Grzegorz A. Czapski*, Marta Matuszewska*, Magdalena Cieślik, Joanna B. Strosznajder

Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland

* These authors contributed equally to this work

Folia Neuropathol 2024; 62 (2): 1-9 *DOI: https://doi.org/10.5114/fn.2024.138140*

Abstract

The neuroinflammation is a crucial component of virtually all neurodegenerative disorders, including Alzheimer's disease (AD). The bacterial lipopolysaccharide (LPS), a potent activator of the innate immune system, was suggested to influence or even trigger the neuropathological alterations in AD. LPS-induced neuroinflammation involves changes in transcription of several genes, thus controlling these molecular processes may be a potentially efficient strategy to attenuate the progression of AD. Since genome-wide association studies showed that the majority of AD-related genetic risk factors (AD-GRF) are connected to the immune system, our aim was to identify AD-GRF affected in the hippocampus by LPS-induced systemic inflammatory response (SIR). Moreover, we analysed the role of bromodomain and extraterminal domain (BET) proteins, the readers of the acetylation code, in controlling the transcription of selected AD-GRF in the brain during neuroinflammation.

In our study, we used a mouse model of LPS-induced SIR and mouse microglial BV2 cells. JQ1 was used as an inhibitor of BET proteins. The level of mRNA was analysed using microarrays and qPCR.

Our data demonstrated that among the established AD-GRF, only the expression of Cd33 was significantly upregulated in the hippocampus during SIR. In parallel, we observed an increase in the expression of Brd4, a BET family member. JQ1 prevented an LPS-evoked increase in Cd33 expression in the hippocampus of mice. Moreover, JQ1 reduced Cd33 expression in BV2 microglial cells stimulated with blood serum from LPS-treated mice.

Our study suggests that LPS-evoked SIR may increase Cd33 gene expression in the brain, and inhibition of BET proteins through suppression of Cd33 expression could be a promising strategy in prevention or in slowing down the progression of neuroinflammation and may potentially affect the pathomechanism of AD.

Key words: *Alzheimer's disease, systemic inflammatory response, endotoxin, bromodomain and extraterminal domain proteins, hippocampus, microglia.*

Introduction

During the last decades, a growing body of epidemiological data has indicated a substantial role of the immune system and inflammation in the pathogenesis/pathomechanism of Alzheimer's disease (AD). The association between the frequency of viral and bacterial infections and the risk of AD was presented during the last decades [10,22,54]. Several studies have demonstrated the advantageous effect of long-term use

Communicating author:

Grzegorz A. Czapski, Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 Pawińskiego St., 02-106 Warsaw, Poland, e-mail: gczapski@imdik.pan.pl

Received: 04.10.2023, **Accepted:** 23.02.2024, **Online publication:** 2024

of non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of developing AD [13,33,46]. Additionally, analysis of human brains demonstrated that neuroinflammation, changes in cytokine profiles, and markers of microglia and astrocyte activation are important components of Alzheimer's pathology [1].

Recent hypotheses have highlighted the role of Gram-negative bacteria and their lipopolysaccharides (LPS) in the pathomechanism of AD [9,21,36,60]. The genome-wide association studies (GWAS) established a set of 29 genes whose polymorphism significantly affects the risk of developing AD (AD-GRF; AD-related genetic risk factors) [4]. Interestingly, many of these genes are related to the innate mechanisms of the immune system and to the function of microglia, which suggests the crucial role of neuroinflammation and microglial phagocytosis in the pathomechanism of AD [51]. LPS is a potent bacterial endotoxin that is highly resistant to degradation by mammalian enzymes, resulting in a persistent inflammatory stimulus. Intraperitoneal injection of LPS is a well-established *in vivo* model of the systemic inflammatory response (SIR) worsening brain function, cognitive functions, and memory [19,23,26,34]. However, the impact of SIR on the transcription of AD-GRF in the brain has never been studied.

The modulation of neuroinflammatory processes was demonstrated to protect the brain from LPS-induced dysfunction [17,59]. Among several anti-inflammatory strategies, inhibition of bromodomain and extraterminal domain (BET) proteins appears to be especially interesting. BET proteins are important epigenetic regulators of gene expression [12]. They are the readers of the acetylation code that in cooperation with transcription factors control the transcription [57]. Several BET inhibitors have shown anti-inflammatory properties in animal models of AD [39,43,49,50].

Therefore, in our study, we studied the impact of LPS-evoked systemic inflammation on the transcription of AD-GRF in the hippocampus of mice. Moreover, we analysed whether pharmacological inhibition of BET proteins may attenuate LPS-evoked alterations.

Material and methods

Animals and experimental design

The experiments were carried out on 3-month-old male C57BL/6J mice supplied by the Animal House of the Mossakowski Medical Research Institute, Polish Academy of Sciences (Warsaw, Poland). The animals were maintained under standard conditions, with controlled temperature (22°C ±10%) and humidity (55% ±10%). All of the experiments conducted on the animals were approved by the II Local Ethics Committee for Animal Experimentation in Warsaw (permission WAW2/060/2020) and carried out following EU Directive 2010/63/EU on the protection of animals used for scientific purposes, and complying with the ARRIVE guidelines. All efforts were made to minimize animal suffering and reduce the animals' number. All manipulations were performed quickly and gently to reduce the animal's stress.

(S)-(+)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate (JQ1), a highly specific and potent inhibitor of BET proteins (Sigma-Aldrich, St. Louis, MO, USA), solution was prepared as defined previously [35]. Shortly, it was dissolved in dimethyl sulfoxide and mixed 1 : 10 with 10% 2-hydroxypropyl-β-cyclodextrin. LPS (from *E. coli* serotype O55:B5; toxicity 1.5×10^7 EU/mg; Sigma-Aldrich) was dissolved in saline. All treatments were performed in the morning. Animals were intraperitoneally (i.p.) injected with JQ1 (50 mg/kg b.w. or respective volume of the vehicle) and 30 min later with LPS (i.p.; 1 mg/kg or respective volume of the vehicle). After 3 and 12 h, animals were anesthetized by isoflurane inhalation and decapitated. The blood was collected 12 hours after the administration of LPS. Directly after the formation of the clot, samples were centrifuged at 1000 × g for 5 minutes to separate the serum and immediately frozen and stored at –85°C.

Microarray analysis of gene expression

Twelve hours after administration of LPS (i.p.; 1 mg/kg b.w.), total RNA from the perfused mouse hippocampus was isolated and analysed by using the Affymetrix Gene Chip Mouse genome 430 2.0. (Affymetrix Inc., Santa Clara, CA, USA), as described previously [21]. The data were normalized with the GC-RMA method and log2 transformed. Full microarray data (CEL files) are available in a public repository at: https://osf.io/x3jub/.

Cell culture experiment

Murine microglial BV2 cells were obtained from Elabscience Biotechnology Inc. (Houston, TX, USA) [6]. The cells were cultured in RPMI medium supplemented with 10% FBS, 2 mM L-glutamine, 50 µg/ml streptomycin, and 50 units/ml penicillin in a 5% CO_2 atmosphere at 37°C. The passages below the twentieth were used. The cells were frequently tested to avoid mycoplasma contamination.

JQ1 was dissolved in DMSO at a 10 mM stock solution and then it was diluted with a culture medium and added to cells at a 50 nM concentration. Thirty minutes after JQ1 the murine blood serum from con-

trol animals or from LPS-treated animals was added to BV2 cells (final concentration: 2% v/v). After 12 h incubation, cells were washed twice with PBS, and RNA was isolated, as described below. In all experiments, the respective volume of vehicle was consequently added to corresponding groups.

PCR analysis of gene expression

Total RNA from the mouse hippocampus and from BV2 cells was extracted using TRI-reagent as described previously [44]. Reverse transcription and quantitative PCR were performed using pre-developed TaqMan Gene Expression Assays: *Cd33* (Mm00491152_m1), *Brd2* (Mm01271171_g1), *Brd3* (Mm01326697_m1), *Brd4* (Mm01350417_m1), *Tnf* (Mm00443258_m1), and *Gusb* (Mm01197698_m1) (Applied Biosystems, Foster City, CA, USA) [44]. The relative levels of mRNA were calculated using the ΔΔCt method. *Gusb* was used as a reference gene.

Statistics

Statistical analysis of data was performed with GraphPad Prism version 8.0 (GraphPad Software, San Diego, CA, USA) using Student's *t*-test or one-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparisons test. The distribution of the data was analysed using the Shapiro-Wilk normality test. *N* refers to the number of animals in the experimental group or to the number of independent experiments *in vitro*.

Results

Systemic injection of LPS is a widely used model of the systemic inflammatory response (SIR). Our previous studies demonstrated that SIR evoked by a moderate dose of LPS (1 mg/kg b.w.) induced acute but transient neuroinflammatory processes in the brain, including alterations in gene expression patterns, oxidative stress, and changes in the activity of several enzymes, among them Gsk-3β, Cdk5 and other kinases [15-21,34]. These molecular alterations were accompanied by short-lasting sickness behaviour and cognitive impairment [34]. In the present study, we focused on genes that were identified by GWAS studies as AD-linked genetic risk factors [4,5]. In our analysis, we also included genes that cause a fully penetrant monogenic form of AD: *Psen1*, *Psen2,* and *App*. As shown in Figure 1, our microarray data revealed that twelve hours after peripheral injection of LPS into a mouse, the mRNA level of several AD-GRF in the hippocampus was altered. The most pronounced change was noticed



Fig. 1. Changes in mRNA levels of 31 genetic risk factors for Alzheimer's disease (AD) in the hippocampus of mice subjected to systemic inflammatory response (SIR) evoked by lipopolysaccharide (LPS). Microarray analysis was performed 12 hours after intraperitoneal administration of LPS. Each data point represents a mean value for a specific probe. The statistically significant change in expression ($p < 0.05$), compared to the control, was indicated by open squares. $N = 4$. FC – fold change.



Fig. 2. Changes in mRNA levels of genes coding BET proteins and Cd33 in the mouse hippocampus 3 and 12 h after intraperitoneal injection of lipopolysaccharide (LPS). **A**) The impact of LPS on the transcription of *Brd2*, *Brd3*, and *Brd4* genes. The respective control level was presented as a dotted line. **B**) The effect of BET inhibitor, JQ1, on LPS-evoked alterations of *Cd33* expression in the hippocampus. The mRNA level was analysed by using the qPCR method. The data represent the mean values ± SEM from 6 animals. *,***$p < 0.05$, and $p < 0.001$, compared to the corresponding control, respectively; ##$p < 0.01$, compared to the LPS group.



Fig. 3. The effect of BET proteins inhibitor, JQ1, on the mRNA level of *Cd33* and *Tnf* in the mouse microglial BV2 cells after 12 h incubation in the presence of blood serum from control and lipopolysaccharide (LPS)-treated mice. Mice received intraperitoneal injections of saline or LPS, then after 12 h blood was collected, and serum was prepared. BV2 cells were incubated in the presence of JQ1 (50 nM) for 30 min, then mice blood serum was added and incubation was continued for 12 h. The mRNA levels of *Cd33* (**A**) and the mRNA level of *Tnf* (**B**) were analysed by using the qPCR method. The data represent the mean values ± SEM from 5 independent experiments. *,***$p < 0.05$, and $p < 0.001$, compared to the corresponding control, respectively; ###$p < 0.001$, compared to the respective LPS group.

for the *Cd33* gene, whose expression was upregulated by 58% ($p < 0.001$).

The alterations in *Cd33* expression were verified on a separate set of animals by using the quantitative PCR method. Additionally, the effect of JQ1, a very selective inhibitor of BET proteins, was analysed. Our data demonstrated (Fig. 2A) that among the three brain-expressed isoforms of BET proteins (Brd2, Brd3, and Brd4), the expression of the *Brd4* gene increased three hours after injection of LPS. As shown in Figure 2B, three hours

after administration of LPS, neither LPS nor JQ1 affected the mRNA level for *Cd33*. However, twelve hours after peripheral administration of LPS, the mRNA level for the *Cd33* gene was significantly increased in the hippocampus, probably in microglia cells. Moreover, JQ1 efficiently prevented LPS-evoked upregulation of *Cd33*.

To confirm that inflammatory conditions increase the expression of *Cd33* in microglial cells, in a separate experiment *in vitro*, we analysed the impact of JQ1 on the level of *Cd33* mRNA in stimulated mouse microglial BV2 cells. As demonstrated in Figure 3, stimulation of BV2 cells for twelve hours with blood serum from LPS-treated mice induced a substantial increase in the expression of *Cd33* and *Tnf* genes, compared to cells incubated with serum from control mice. At this timepoint, JQ1 significantly reduced the mRNA level of *Cd33*, in both stimulated (79% decrease) and non-stimulated cells (72% decrease), but did not affect the expression of the *Tnf* gene.

Discussion

Our data demonstrated hippocampal expression of 29 genes that were identified as bearing single nucleotide polymorphisms affecting the risk of developing AD [4]. In addition, we examined genes that are responsible for a genetic form of AD: *Psen1*, *Psen2*, and *App*. We hypothesized that inflammation may evoke changes in the expression of these genes in the brain, which, in consequence, might contribute to the pathomechanism of AD. By using a mouse model of the systemic inflammatory response (SIR) evoked by peripheral administration of LPS we identified a significant increase in the mRNA level for *Cd33* in the hippocampus. To our knowledge, the change in CD33 expression in the brain due to SIR has not been previously reported, but it seems that it could promote molecular alterations leading to neurodegeneration.

It was recently suggested that bacterial endotoxins (LPS) derived from the gut microbiota or originating from invading bacteria may significantly contribute to stimulation or the overactivation of neuroinflammation in AD [26,36,61], however, the mechanism remains unclear. Therefore, the identification of specific molecules that mediate LPS-related neuroinflammation may potentially facilitate the development of novel targets for therapy in AD. This disease is the major cause of dementia in the elderly, but despite decades of extensive research, the primary trigger is still unknown, and we still do not have efficient curation. Epidemiological data, GWAS, and analysis of human AD brains suggested neuroinflammation as a driving force in the pathomechanism or even pathogenesis of AD [1,4,47].

CD33 (Siglec-3) is a member of the Siglec family (sialic acid-binding immunoglobulin-like lectins), which in the brain is expressed mainly in microglial cells [14,25]. In humans, due to alternative splicing, two isoforms of CD33 are synthesised: a full-length protein hCD33M (M = 'Major'; 90%), and devoid of exon 2 short protein hCD33m (m = 'minor'; 10%) [25]. There is compelling evidence that CD33 affects the pathology associated with Aβ accumulation in AD by impairing Aβ clearance by microglia active during neuroinflammation [30]. A level of sialoglycan ligand for CD33, $(RPTP\zeta)^{S3L}$, is about twofold higher in the brains of AD patients than in the age-matched healthy controls [28]. Also, a large family-based GWAS indicated *CD33* as one of the top-level AD risk-related genes [3,58]. Two single nucleotide polymorphisms (SNP) in the *CD33* gene are considered crucial: rs3865444, which is located upstream of *CD33*, and rs12459419, which is located within the second exon [3]. The risk allele of rs3865444 evokes higher cell surface expression of CD33 and is related to the decline of cognitive functions [7,52]. The occurrence of the minor (protective) rs3865444 polymorphism was related with a decreased level of functional CD33 protein and with decreased levels of insoluble Aβ in the brains of AD patients [30]. The common allele rs12459419 favours the synthesis of a full-length CD33M, whereas the protective allele favours the synthesis of a short CD33m isoform. Interestingly, that 'protective' allele was suggested to be derived, human-specific, and reflect evolutionary pressure for longevity in humans [53]. Also, rs3826656 and rs2455069 have been associated with a higher risk of AD [3,55]. In AD brains, the level of CD33 is increased and correlates with a higher Aβ level and cognitive decline. Moreover, experimental studies demonstrated that CD33 reduces the clearance of $A\beta_{42}$ by microglia; therefore, it was suggested that CD33 protein may play a crucial role in the pathomechanism of AD, and its attenuation may be beneficial [31]. Indeed, the inactivation of CD33 in genetic mouse models of AD decreased levels of insoluble $A\beta_{1\text{-}42}$ in the brain and alleviated Aβ plaque pathology [29,30]. Moreover, expression of the human full-length variant of CD33 in 5×FAD mice increased Aβ pathology in the brain, but the protective variant had the opposite effect [24].

An important question arises about the impact of aging on the brain expression of CD33, which could potentially play a key role in the pathomechanism of AD. Unfortunately, the available data are inconsistent. In BALB/c mice, aging had no impact on *Cd33* expression level (GEO Profiles:12080108) [27]. Also, studies on human post-mortem brain tissues gave varying results (GEO profiles 5718268 and 117386467) [41,42], therefore, additional research is necessary to answer this question.



Fig. 4. Systemic inflammatory response (SIR), a trigger of CD33, could lead to neurodegeneration and Alzheimer's disease (AD). Lipopolysaccharide (LPS)-evoked SIR induces neuroinflammatory processes [16,20], accumulation of Aβ [37,56], and a BET-dependent increase in the expression of the *Cd33* – AD risk factor in the hippocampus. These processes may contribute to neurodegeneration and could be associated with AD. Enhanced expression of CD33 leads to inhibition of microglial phagocytosis and, in consequence, an increase in Aβ load in the brain. JQ1, an inhibitor of BET proteins, prevents SIR-related upregulation of *Cd33* expression.

Another important issue is the similarity between human and murine CD33. The fundamental physiological differences between humans and mice are evident, but still, a relatively large part of the human genome (about 40%) has a homologous locus in the mouse genome [38]. The human *CD33* and mouse *Cd33* genes have a similar structure and chromosomal position, and their protein sequence identity is 62% within extracellular domains [25]. The murine Cd33 lacks the characteristic ITIM (immunoreceptor tyrosine-based inhibitory motif) domain, which suggests that murine Cd33 may not precisely replicate the action of human CD33. Even though gene control systems are similar in mice and humans, some RNA expression diversity exists [11,40]. The previous reports demonstrated some variances in expression patterns and ligand recognition between human and murine CD33 [8]. However, both human and mouse CD33 inhibited phagocytosis of Aβ [30]. Therefore, future research should be performed to confirm our observations in human cells.

Because inhibitors of BET proteins were demonstrated to efficiently attenuate several LPS-evoked changes [2,32], the second goal of this study was to analyse the impact of JQ1, an inhibitor of BET proteins, on LPS-changed expression of AD-GRF genes in the hippocampus during systemic inflammation. In mice, JQ1 is well tolerated even after chronic treatment, and it efficiently enters the brain (AUC_{brain}/AUC_{plasma} = 98%) [43,45,48]. Our previous data indicated that in mouse microglia *in vitro* JQ1 reduced the expression of the *Cd33* gene by 83% [44]. In the current study, it was observed that JQ1 reduced the level of *Cd33* mRNA in the mouse hippocampus during SIR, but had no effect in the corresponding control. We can assume the cerebral action of JQ1, therefore, its inhibitory effect on microglial phagocytosis [44] cannot be completely excluded. Based on these data, we propose that inhibitors of BET proteins may prevent inflammation-evoked changes in the expression of the *Cd33* gene and, therefore, may be used to attenuate CD33-dependent signalling.

In summary, our study demonstrated the upregulation of the *Cd33*, a well-established genetic risk factor for AD, in the mouse hippocampus during LPS-evoked systemic inflammation. Moreover, our data indicated that an inhibitor of BET proteins prevented the activation of the *Cd33* gene in hippocampal cells during SIR. These results suggest that inhibitors of BET proteins may be suitable for prevention or for slowing down the progression of neuroinflammatory processes, which may be critical events in brain function and in the pathogenesis/pathomechanism of AD (Fig. 4).

Acknowledgments

The authors thank Elżbieta Gawinek for technical support.

Datasets/data availability statement

The data supporting the findings of this study are available on request from the corresponding author. Full microarray data (CEL files) are available in a public repository at: https://osf.io/x3jub/.

Funding

This research was supported by the National Science Centre, grant number 2018/31/B/NZ4/01379.

Disclosures

The study was approved by the II Local Ethics Committee for Animal Experimentation in Warsaw (permission WAW2/060/2020).

The authors report no conflict of interest.

References

1. Barroeta-Espar I, Weinstock LD, Perez-Nievas BG, Meltzer AC, Siao Tick Chong M, Amaral AC, Murray ME, Moulder KL, Morris JC, Cairns NJ, Parisi JE, Lowe VJ, Petersen RC, Kofler J, Ikonomovic MD, López O, Klunk WE, Mayeux RP, Frosch MP, Wood LB, Gomez-Isla T. Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. Neurobiol Dis 2019; 121: 327-337.
2. Belkina AC, Nikolajczyk BS, Denis GV. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol 2013; 190: 3670-3678.
3. Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BM, Hooli B, Divito J, Ionita I, Jiang H, Laird N, Moscarillo T, Ohlsen KL, Elliott K, Wang X, Hu-Lince D, Ryder M, Murphy A, Wagner SL, Blacker D, Becker KD, Tanzi RE. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 2008; 83: 623-632.
4. Bertram L, Tanzi RE. Alzheimer disease risk genes: 29 and counting. Nat Rev Neurol 2019; 15: 191-192.
5. Bertram L, Tanzi RE. Genomic mechanisms in Alzheimer's disease. Brain Pathol 2020; 30: 966-977.
6. Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F. Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol 1990; 27: 229-237.
7. Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboywa S, Lee M, Von Korff A, Morris MC, Evans DA, Johnson K, Sperling RA, Schneider JA, Bennett DA, De Jager PL. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci 2013; 16: 848-850.
8. Brinkman-Van der Linden EC, Angata T, Reynolds SA, Powell LD, Hedrick SM, Varki A. CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice. Mol Cell Biol 2003; 23: 4199-4206.
9. Brown GC. The endotoxin hypothesis of neurodegeneration. J Neuroinflammation 2019; 16: 180.
10. Bu XL, Yao XQ, Jiao SS, Zeng F, Liu YH, Xiang Y, Liang CR, Wang QH, Wang X, Cao HY, Yi X, Deng B, Liu CH, Xu J, Zhang LL, Gao CY, Xu ZQ, Zhang M, Wang L, Tan XL, Xu X, Zhou HD, Wang YJ. A study on the association between infectious burden and Alzheimer's disease. Eur J Neurol 2015; 22: 1519-1525.
11. Cheng Y, Ma Z, Kim BH, Wu W, Cayting P, Boyle AP, Sundaram V, Xing X, Dogan N, Li J, Euskirchen G, Lin S, Lin Y, Visel A, Kawli T, Yang X, Patacsil D, Keller CA, Giardine B, Kundaje A, Wang T, Pennacchio LA, Weng Z, Hardison RC, Snyder MP. Principles of regulatory information conservation between mouse and human. Nature 2014; 515: 371-375.
12. Cheung KL, Kim C, Zhou MM. The functions of BET proteins in gene transcription of biology and diseases. Front Mol Biosci 2021; 8: 728777.
13. Côté S, Carmichael PH, Verreault R, Lindsay J, Lefebvre J, Laurin D. Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease. Alzheimers Dement 2012; 8: 219-226.
14. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007; 7: 255-266.
15. Czapski GA, Adamczyk A, Strosznajder RP, Strosznajder JB. Expression and activity of PARP family members in the hippocampus during systemic inflammation: their role in the regulation of prooxidative genes. Neurochem Int 2013; 62: 664-673.
16. Czapski GA, Cakala M, Chalimoniuk M, Gajkowska B, Strosznajder JB. Role of nitric oxide in the brain during lipopolysaccharide-evoked systemic inflammation. J Neurosci Res 2007; 85: 1694-1703.
17. Czapski GA, Cakala M, Gajkowska B, Strosznajder JB. Poly(ADP-ribose) polymerase-1 inhibition protects the brain against systemic inflammation. Neurochem Int 2006; 49: 751-755.
18. Czapski GA, Cieślik M, Białopiotrowicz E, Lukiw WJ, Strosznajder JB. Down-regulation of cyclin D2 in amyloid β toxicity, inflammation, and Alzheimer's disease. PLoS One 2021; 16: e0259740.
19. Czapski GA, Gajkowska B, Strosznajder JB. Systemic administration of lipopolysaccharide induces molecular and morphological alterations in the hippocampus. Brain Res 2010; 1356: 85-94.
20. Czapski GA, Gassowska M, Wilkaniec A, Chalimoniuk M, Strosznajder JB, Adamczyk A. The mechanisms regulating cyclin-dependent kinase 5 in hippocampus during systemic inflammatory response: The effect on inflammatory gene expression. Neurochem Int 2016; 93: 103-112.
21. Czapski GA, Zhao Y, Lukiw WJ, Strosznajder JB. Acute systemic inflammatory response alters transcription profile of genes related to immune response and Ca(2+) homeostasis in hippocampus; relevance to neurodegenerative disorders. Int J Mol Sci 2020; 21: 7838.
22. Douros A, Santella C, Dell'Aniello S, Azoulay L, Renoux C, Suissa S, Brassard P. Infectious disease burden and the risk of Alzheimer's disease: A population-based study. J Alzheimers Dis 2021; 81: 329-338.
23. Engler-Chiurazzi EB, Russell AE, Povroznik JM, McDonald KO, Porter KN, Wang DS, Hammock J, Billig BK, Felton CC, Yilmaz A, Schreurs BG, O'Callaghan JD, Zwezdaryk KJ, Simpkins JW. Intermittent systemic exposure to lipopolysaccharide-induced inflammation disrupts hippocampal long-term potentiation and impairs cognition in aging male mice. Brain Behav Immun 2023; 108: 279-291.
24. Eskandari-Sedighi G, Crichton M, Zia S, Gomez E, Laurent CDS, Cortez LM, Patel ZH, Sidhu G, Sarkar S, Aghanya V, Sim VL, Tan Q, Julien O, Plemel JR, Macauley MS. Alzheimer's disease associated isoforms of human CD33 distinctively modulate microglial cell responses in 5XFAD mice. bioRxiv 2023 [Preprint]; July 4, 2023 (cited 2024 Jan 9). Available from: https://doi.org/10.1101/2023.07.04.547548.
25. Eskandari-Sedighi G, Jung J, Macauley MS. CD33 isoforms in microglia and Alzheimer's disease: Friend and foe. Mol Aspects Med 2023; 90: 101111.
26. Ganz T, Fainstein N, Elad A, Lachish M, Goldfarb S, Einstein O, Ben-Hur T. Microbial pathogens induce neurodegeneration in Alzheimer's disease mice: protection by microglial regulation. J Neuroinflammation 2022; 19: 5.
27. Godbout JP, Chen J, Abraham J, Richwine AF, Berg BM, Kelley KW, Johnson RW. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J 2005; 19: 1329-1331.
28. Gonzalez-Gil A, Porell RN, Fernandes SM, Maenpaa E, Li TA, Li T, Wong PC, Aoki K, Tiemeyer M, Yu ZJ, Orsburn BC, Bumpus NN, Matthews RT, Schnaar RL. Human brain sialoglycan ligand for CD33, a microglial inhibitory Siglec implicated in Alzheimer's disease. J Biol Chem 2022; 298: 101960.
29. Griciuc A, Federico AN, Natasan J, Forte AM, McGinty D, Nguyen H, Volak A, LeRoy S, Gandhi S, Lerner EP, Hudry E, Tanzi RE, Maguire CA. Gene therapy for Alzheimer's disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation. Hum Mol Genet 2020; 29: 2920-2935.
30. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE. Alzheimer's dis-

ease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013; 78: 631-643.
31. Griciuc A, Tanzi RE. The role of innate immune genes in Alzheimer's disease. Curr Opin Neurol 2021; 34: 228-236.
32. Hoffner O'Connor M, Berglind A, Kennedy Ng MM, Keith BP, Lynch ZJ, Schaner MR, Steinbach EC, Herzog J, Trad OK, Jeck WR, Arthur JC, Simon JM, Sartor RB, Furey TS, Sheikh SZ. BET protein inhibition regulates macrophage chromatin accessibility and microbiota-dependent colitis. Front Immunol 2022; 13: 856966.
33. in t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-1521.
34. Jacewicz M, Czapski GA, Katkowska I, Strosznajder RP. Systemic administration of lipopolysaccharide impairs glutathione redox state and object recognition in male mice. The effect of PARP-1 inhibitor. Folia Neuropathol 2009; 47: 321-328.
35. Jostes S, Nettersheim D, Fellermeyer M, Schneider S, Hafezi F, Honecker F, Schumacher V, Geyer M, Kristiansen G, Schorle H. The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo. J Cell Mol Med 2017; 21: 1300-1314.
36. Kim HS, Kim S, Shin SJ, Park YH, Nam Y, Kim CW, Lee KW, Kim SM, Jung ID, Yang HD, Park YM, Moon M. Gram-negative bacteria and their lipopolysaccharides in Alzheimer's disease: pathologic roles and therapeutic implications. Transl Neurodegener 2021; 10: 49.
37. Kirk RA, Kesner RP, Wang LM, Wu Q, Towner RA, Hoffman JM, Morton KA. Lipopolysaccharide exposure in a rat sepsis model results in hippocampal amyloid-β plaque and phosphorylated tau deposition and corresponding behavioral deficits. Geroscience 2019; 41: 467-481.
38. Kwon SB, Ernst J. Learning a genome-wide score of human-mouse conservation at the functional genomics level. Nat Commun 2021; 12: 2495.
39. Li J, Zhao L, Urabe G, Fu Y, Guo LW. Epigenetic intervention with a BET inhibitor ameliorates acute retinal ganglion cell death in mice. Mol Vis 2017; 23: 149-159.
40. Lin S, Lin Y, Nery JR, Urich MA, Breschi A, Davis CA, Dobin A, Zaleski C, Beer MA, Chapman WC, Gingeras TR, Ecker JR, Snyder MP. Comparison of the transcriptional landscapes between human and mouse tissues. Proc Natl Acad Sci U S A 2014; 111: 17224-17229.
41. Lu T, Aron L, Zullo J, Pan Y, Kim H, Chen Y, Yang TH, Kim HM, Drake D, Liu XS, Bennett DA, Colaiácovo MP, Yankner BA. REST and stress resistance in ageing and Alzheimer's disease. Nature 2014; 507: 448-454.
42. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA. Gene regulation and DNA damage in the ageing human brain. Nature 2004; 429: 883-891.
43. Magistri M, Velmeshev D, Makhmutova M, Patel P, Sartor GC, Volmar CH, Wahlestedt C, Faghihi MA. The BET-bromodomain inhibitor JQ1 reduces inflammation and tau phosphorylation at Ser396 in the brain of the 3xTg model of Alzheimer's disease. Curr Alzheimer Res 2016; 13: 985-995.
44. Matuszewska M, Cieślik M, Wilkaniec A, Strawski M, Czapski GA. The role of bromodomain and extraterminal (BET) proteins in controlling the phagocytic activity of microglia in vitro: Relevance to Alzheimer's disease. Int J Mol Sci 2022; 24: 13.
45. Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, Lemieux ME, Picaud S, Yu RN, Qi J, Knapp S, Bradner JE. Small-molecule inhibition of BRDT for male contraception. Cell 2012; 150: 673-684.
46. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007; 28: 639-647.
47. McGeer PL, Rogers J, McGeer EG. Inflammation, antiinflammatory agents, and Alzheimer's disease: The last 22 years. J Alzheimers Dis 2016; 54: 853-857.
48. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ, 3rd. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011; 108: 16669-16674.
49. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H, White J, Kirilovsky J, Rice CM, Lora JM, Prinjha RK, Lee K, Tarakhovsky A. Suppression of inflammation by a synthetic histone mimic. Nature 2010; 468: 1119-1123.
50. Peeters JG, Vervoort SJ, Tan SC, Mijnheer G, de Roock S, Vastert SJ, Nieuwenhuis EE, van Wijk F, Prakken BJ, Creyghton MP, Coffer PJ, Mokry M, van Loosdregt J. Inhibition of super-enhancer activity in autoinflammatory site-derived T cells reduces disease-associated gene expression. Cell Rep 2015; 12: 1986-1996.
51. Podleśny-Drabiniok A, Marcora E, Goate AM. Microglial Phagocytosis: A disease-associated process emerging from Alzheimer's disease genetics. Trends Neurosci 2020; 43: 965-979.
52. Raj T, Ryan KJ, Replogle JM, Chibnik LB, Rosenkrantz L, Tang A, Rothamel K, Stranger BE, Bennett DA, Evans DA, De Jager PL, Bradshaw EM. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility. Hum Mol Genet 2014; 23: 2729-2736.
53. Schwarz F, Springer SA, Altheide TK, Varki NM, Gagneux P, Varki A. Human-specific derived alleles of CD33 and other genes protect against postreproductive cognitive decline. Proc Natl Acad Sci U S A 2016; 113: 74-79.
54. Sun J, Ludvigsson JF, Ingre C, Piehl F, Wirdefeldt K, Zagai U, Ye W, Fang F. Hospital-treated infections in early- and mid-life and risk of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis: A nationwide nested case-control study in Sweden. PLoS Med 2022; 19: e1004092.
55. Tortora F, Rendina A, Angiolillo A, Di Costanzo A, Aniello F, Donizetti A, Febbraio F, Vitale E. CD33 rs2455069 SNP: Correlation with Alzheimer's disease and hypothesis of functional role. Int J Mol Sci 2022; 23: 3629.
56. Wang LM, Wu Q, Kirk RA, Horn KP, Ebada Salem AH, Hoffman JM, Yap JT, Sonnen JA, Towner RA, Bozza FA, Rodrigues RS, Morton KA. Lipopolysaccharide endotoxemia induces amyloid-β and p-tau formation in the rat brain. Am J Nucl Med Mol Imaging 2018; 8: 86-99.
57. Wang N, Wu R, Tang D, Kang R. The BET family in immunity and disease. Signal Transduct Target Ther 2021; 6: 23.
58. Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, Rongve A, Børte S, Winsvold BS, Drange OK, Martinsen AE, Skogholt AH, Willer C, Bråthen G, Bosnes I, Nielsen JB, Fritsche LG, Thomas LF, Pedersen LM, Gabrielsen ME, Johnsen MB, Meisingset TW, Zhou W, Proitsi P, Hodges A, Dobson R, Velayudhan L, Heilbron K, Auton A, Sealock JM, Davis LK, Pedersen NL, Reynolds CA, Karlsson IK, Magnusson S, Stefansson H, Thordardottir S, Jonsson PV, Snaedal J, Zettergren A, Skoog I, Kern S, Waern M, Zetterberg H, Blennow K, Stordal E, Hveem K, Zwart JA, Athanasiu L, Selnes P, Saltvedt I, Sando SB, Ulstein I, Djurovic S, Fladby T, Aarsland D, Selbæk G, Ripke S, Stefansson K, Andreassen OA, Posthuma D. A genome-wide association study with 1,126,563

individuals identifies new risk loci for Alzheimer's disease. Nat Genet 2021; 53: 1276-1282.
59. Wilkaniec A, Gassowska-Dobrowolska M, Strawski M, Adamczyk A, Czapski GA. Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity. J Neuroinflammation 2018; 15: 1.
60. Zhao Y, Jaber V, Lukiw WJ. Secretory products of the human GI tract microbiome and their potential impact on Alzheimer's disease (AD): Detection of lipopolysaccharide (LPS) in AD hippocampus. Front Cell Infect Microbiol 2017; 7: 318.
61. Zhao Y, Jaber VR, Pogue AI, Sharfman NM, Taylor C, Lukiw WJ. Lipopolysaccharides (LPSs) as potent neurotoxic glycolipids in Alzheimer's disease (AD). Int J Mol Sci 2022; 23: 12671.